IBO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.0K
-57.1%
7.0K
+0.0%
7.0K
-61.1%
18.0K
+157.1%
7.0K
Cost of Revenue
19.0K
0
-100.0%
422.0K
+42100.0%
1.0K
-94.7%
19.0K
Gross Profit
-16000
-328.6%
7.0K
+101.7%
-415000
-2541.2%
17.0K
+241.7%
-12000
Operating Expenses
686.0K
-70.1%
2.3M
+209.0%
743.0K
-23.0%
965.0K
-15.4%
1.1M
R&D
76.0K
+65.2%
46.0K
-58.2%
110.0K
+111.5%
52.0K
-30.7%
75.0K
SG&A
259.0K
-86.2%
1.9M
+631.1%
257.0K
-48.3%
497.0K
-24.5%
658.0K
Operating Income
-702000
+69.3%
-2289000
-97.7%
-1158000
-22.2%
-948000
+17.8%
-1153000
EBITDA
-418000
+79.1%
-2004000
-129.8%
-872000
-32.1%
-660000
+23.7%
-865000
Net Income
-700000
+69.4%
-2284000
-143.6%
5.2M
+454.9%
-1475000
+89.7%
-14352000
EPS (Basic)
$-0.01
+50.0%
$-0.02
-133.3%
$0.06
+150.0%
$-0.12
+89.8%
$-1.18
EPS (Diluted)
$-0.01
+50.0%
$-0.02
-133.3%
$0.06
+150.0%
$-0.12
+89.8%
$-1.18
Shares (Diluted)
107.8M
+0.0%
107.8M
+20.1%
89.8M
+636.7%
12.2M
+0.0%
12.2M
Impact BioMedical (IBO) โ€” Financials